David M. Hyman

47.2k total citations · 10 hit papers
221 papers, 11.5k citations indexed

About

David M. Hyman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, David M. Hyman has authored 221 papers receiving a total of 11.5k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Oncology, 77 papers in Pulmonary and Respiratory Medicine and 71 papers in Molecular Biology. Recurrent topics in David M. Hyman's work include Cancer Genomics and Diagnostics (57 papers), Lung Cancer Treatments and Mutations (40 papers) and Colorectal Cancer Treatments and Studies (27 papers). David M. Hyman is often cited by papers focused on Cancer Genomics and Diagnostics (57 papers), Lung Cancer Treatments and Mutations (40 papers) and Colorectal Cancer Treatments and Studies (27 papers). David M. Hyman collaborates with scholars based in United States, Spain and France. David M. Hyman's co-authors include José Baselga, Neil Vasan, Ahmet Zehir, Michael F. Berger, David B. Solit, Marc Ladanyi, Barry S. Taylor, Maria E. Arcila, Alexander Drilon and Jaclyn F. Hechtman and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

David M. Hyman

211 papers receiving 11.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A view on drug resistance in cancer

2019 1.9k citations José Baselga, David M. Hyman et al. profile →
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

2017 738 citations Diego Chowell, Luc G.T. Morris et al. Science profile →
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes

2017 521 citations Ahmet Zehir, Philip Jonsson et al. profile →
Small molecules, big impact: 20 years of targeted therapy in oncology

2020 416 citations David M. Hyman et al. profile →
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention

2018 369 citations Ryan Ptashkin, Emmet Jordan et al. Clinical Cancer Research profile →
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

2019 366 citations James P. Solomon, Kerry Mullaney et al. profile →
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

2019 360 citations Vicky Makker, David M. Hyman et al. profile →
Genome doubling shapes the evolution and prognosis of advanced cancers

2018 343 citations Craig M. Bielski, Ahmet Zehir et al. Nature Genetics profile →
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions

2017 331 citations Jaclyn F. Hechtman, Ryma Benayed et al. The American Journal of Surgical Pathology profile →
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden

2019 289 citations Ryma Benayed, Michael Offin et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by David M. Hyman

Since Specialization

Citations

This map shows the geographic impact of David M. Hyman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Hyman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Hyman more than expected).

Fields of papers citing papers by David M. Hyman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Hyman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Hyman. The network helps show where David M. Hyman may publish in the future.

Co-authorship network of co-authors of David M. Hyman

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Hyman. A scholar is included among the top collaborators of David M. Hyman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Hyman. David M. Hyman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations 2021 ·Clinical Cancer Research ·Elio Adib, Katarzyna Klonowska, Krinio Giannikou, T. Khanh, (unknown), (unknown), (unknown), (unknown), (unknown), Lynette M. Sholl, Junko Tsuji, David M. Hyman, (unknown), Geoffrey I. Shapiro, Hebert Alberto Vargas, James J. Harding, Martin H. Voss, Gopa Iyer, David J. Kwiatkowski	37
2	Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing 2020 ·Clinical Cancer Research ·Martee L. Hensley, Shweta S. Chavan, David B. Solit, Rajmohan Murali, Robert A. Soslow, Sarah Chiang, Achim A. Jungbluth, Chaitanya Bandlamudi, Preethi Srinivasan, William D. Tap, Evan Rosenbaum, Barry S. Taylor, Mark T.A. Donoghue, David M. Hyman	67
3	Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers 2020 ·Cancer Discovery ·Vivek Subbiah, Igor Puzanov, Jean‐Yves Blay, Ian Chau, A. Craig Lockhart, Noopur Raje, Juergen Wolf, José Baselga, Funda Meric‐Bernstam, Jason Roszik, Eli L. Diamond, Gregory J. Riely, Eric J. Sherman, Todd Riehl, Bethany Pitcher, David M. Hyman	86
4	Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted ⁸⁹Zr-Pertuzumab PET/CT 2020 ·Radiology ·Gary A. Ulaner, Jorge A. Carrasquillo, Christopher C. Riedl, Randy Yeh, Vaios Hatzoglou, Dara S. Ross, Komal Jhaveri, Sarat Chandarlapaty, David M. Hyman, Brian M. Zeglis, Serge K. Lyashchenko, Jason S. Lewis	45
5	High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden breakdown → 2019 ·Clinical Cancer Research ·Ryma Benayed, Michael Offin, Kerry Mullaney, Purvil Sukhadia, Kelly Rios, Patrice Desmeules, Ryan Ptashkin, Helen Won, Jason C. Chang, Darragh Halpenny, Alison M. Schram, Charles M. Rudin, David M. Hyman, Maria E. Arcila, Michael F. Berger, Ahmet Zehir, Mark G. Kris, Alexander Drilon, Marc Ladanyi	289
6	TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations 2019 ·Clinical Cancer Research ·Ezra Y. Rosen, Debra A. Goldman, Jaclyn F. Hechtman, Ryma Benayed, Alison M. Schram, Emiliano Cocco, Sophie Shifman, Yixiao Gong, Ritika Kundra, James P. Solomon, Alberto Bardelli, Maurizio Scaltriti, Alexander Drilon, Alexia Iasonos, Barry S. Taylor, David M. Hyman	115
7	NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma 2018 ·The American Journal of Surgical Pathology ·Sarah Chiang, Paolo Cotzia, David M. Hyman, Alexander Drilon, William D. Tap, Lei Zhang, Jaclyn F. Hechtman, Denise Frosina, Achim A. Jungbluth, Rajmohan Murali, Kay J. Park, Robert A. Soslow, Esther Oliva, A. John Iafrate, Ryma Benayed, Marc Ladanyi, Cristina R. Antonescu	171
8	A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer 2018 ·Clinical Cancer Research ·Johanna C. Bendell, Anna M. Varghese, David M. Hyman, Todd M. Bauer, Shubham Pant, Sophie Callies, Ji Lin, Ricardo Martínez, Enaksha Wickremsinhe, (unknown), Volker Wacheck, Kathleen N. Moore	81
9	Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors 2018 ·Clinical Cancer Research ·David M. Hyman, Naiyer A. Rizvi, Ronald B. Natale, Deborah K. Armstrong, Michael J. Birrer, Lawrence D. Recht, Efrat Dotan, Vicky Makker, Thomas Kaley, (unknown), Matthew Gribbin, Jennifer McDevitt, Dominic W. Lai, Mohammed M. Dar	38
10	Genome doubling shapes the evolution and prognosis of advanced cancers breakdown → 2018 ·Nature Genetics ·Craig M. Bielski, Ahmet Zehir, Alexander Penson, Mark T.A. Donoghue, Walid K. Chatila, Joshua Armenia, Matthew T. Chang, Alison M. Schram, Philip Jonsson, Chaitanya Bandlamudi, Pedram Razavi, Gopa Iyer, Mark E. Robson, Zsofia K. Stadler, Nikolaus Schultz, José Baselga, David B. Solit, David M. Hyman, Michael F. Berger, Barry S. Taylor	343
11	Next-Generation Sequencing–Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer 2018 ·Journal of Molecular Diagnostics ·Sounak Gupta, Chad Vanderbilt, Paolo Cotzia, Javier Arias‐Stella, Jason C. Chang, Ahmet Zehir, Ryma Benayed, (unknown), Pedram Razavi, David M. Hyman, José Baselga, Michael F. Berger, Marc Ladanyi, Maria E. Arcila, Dara S. Ross	20
12	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition 2017 ·Cancer Research ·Rona Yaeger, Zhan Yao, David M. Hyman, Jaclyn F. Hechtman, Efsevia Vakiani, HuiYong Zhao, Wenjing Su, Lu Wang, Andrew Joelson, Andrea Cercek, José Baselga, Elisa de Stanchina, Leonard B. Saltz, Michael F. Berger, David B. Solit, Neal Rosen	60
13	Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma 2017 ·Clinical Cancer Research ·Vivek Narayan, Stephen J. O’Keefe, Naomi B. Haas, Le Wang, Igor Puzanov, Mary Putt, Annamaria Catino, James C. Fang, Neeraj Agarwal, David M. Hyman, Amanda M. Smith, Brian S. Finkelman, Hari K. Narayan, Steven M. Ewer, Chantal ElAmm, Daniel J. Lenihan, Bonnie Ky	58
14	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma 2017 ·Clinical Cancer Research ·Min Yuen Teo, Richard Bambury, Emily C. Zabor, Emmet Jordan, Hikmat Al‐Ahmadie, Mariel Elena Boyd, Nancy Bouvier, Stephanie A. Mullane, K. Eugene, Nitin Roper, Irina Ostrovnaya, David M. Hyman, Bernard H. Bochner, Maria E. Arcila, David B. Solit, Michael F. Berger, Dean F. Bajorin, Joaquim Bellmunt, Gopa Iyer, Jonathan E. Rosenberg	189
15	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy breakdown → 2017 ·Science ·Diego Chowell, Luc G.T. Morris, Claud Grigg, Jeffrey K. Weber, Robert Samstein, Vladimir Makarov, Fengshen Kuo, Sviatoslav M. Kendall, David Requena, Nadeem Riaz, Benjamin D. Greenbaum, James M. Carroll, Edward B. Garon, David M. Hyman, Ahmet Zehir, David B. Solit, Michael F. Berger, Ruhong Zhou, Naiyer A. Rizvi, Timothy A. Chan	738
16	Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study 2017 ·Blood ·Jia Ruan, Peter Martin, Paul J. Christos, Leandro Cerchietti, Bijal Shah, Stephen J. Schuster, Wayne Tam, Á Rodríguez, David M. Hyman, María Nieves Calvo Vidal, (unknown), Sonali M. Smith, Jakub Svoboda, Richard R. Furman, Morton Coleman, John P. Leonard	7
17	Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities 2015 ·Clinical Cancer Research ·Anne Eaton, Alexia Iasonos, Mrinal M. Gounder, (unknown), Alexander Drilon, (unknown), G. Smith, S. Percy Ivy, David R. Spriggs, David M. Hyman	11
18	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF 2015 ·Molecular Cancer Research ·Jaclyn F. Hechtman, Ahmet Zehir, Rona Yaeger, Lu Wang, Sumit Middha, Tao Zheng, David M. Hyman, David B. Solit, Maria E. Arcila, Laetitia Borsu, Jinru Shia, Efsevia Vakiani, Leonard B. Saltz, Marc Ladanyi	43
19	Prospective Blinded Study of BRAF V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders 2014 ·Cancer Discovery ·David M. Hyman, Eli L. Diamond, Cecile Rose T. Vibat, (unknown), Jason C. Poole, Minal Patel, Veronica R. Holley, Goran Cabrilo, Timothy T. Lu, Maria E. Arcila, Young Rock Chung, Raajit K. Rampal, Mario E. Lacouture, Neal Rosen, Funda Meric‐Bernstam, José Baselga, Razelle Kurzrock, Mark G. Erlander, Filip Jankú, Omar Abdel‐Wahab	84
20	The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials 2012 ·Clinical Cancer Research ·Alexia Iasonos, Mrinal M. Gounder, David R. Spriggs, John F. Gerecitano, David M. Hyman, Sarah Zohar, John O’Quigley	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact